Business

Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension

Chakkarin Burudpakdee, PharmD, Anshul Shah, MS, Vijay N Joish, PhD, Christine H. Divers, PhD, Avin Yaldo, PhD

Stakeholder Perspective

Is It Time for Risk-Sharing Contracts In Specialty Pharmacy?

by Atheer A. Kaddis, PharmD

Business

Impact of the New ACC/AHA Guidelines on the Treatment of High Blood Cholesterol in a Managed Care Setting

Paul S Chan, MD, MSc, Heidi C. Lew, PharmD, Toros Cagla PhD, Brian K. Solow, MD, FAAFP, Karen M. Stockl, PharmD, Josephine N. Tran, PharmD, MS

Stakeholder Perspective

Real-World Consequences of the 2013 ACC/AHA Cholesterol Guidelines for the Prevention of Cardiovascular Disease

by Joseph D. Jackson, PhD

Business

Healthcare Costs Among Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea, Shift Work Disorder, or Narcolepsy

Rashad Carlton, PharmD, MSPH, Cathryn A. Carroll, PhD, Orsolya Lunacsek, PhD, Timothy S. Regan, BPharm, RPh, CPh

Stakeholder Perspective

Out-of-Pocket Cost of Therapy Can Affect Patients’ Excessive Sleepiness and Daytime Functioning

by Teresa DeLuca, MD, MBA

Business

Lessons from the Leucovorin Shortages Between 2009 and 2012 in a Medicare Advantage Population: Where Do We Go from Here?

Mary S. Hayes, PharmD, S. Lane Slabaugh, PharmD, MBA, Melea A. Ward, PharmD, MS, Yihua Xu, PhD

Stakeholder Perspective

Drug Shortages Are Costly to Patients and to Payers

by Joseph P. Fuhr, Jr, PhD

Business

The Health and Economic Effects of Counterfeit Drugs

Erwin A. Blackstone, PhD, Joseph P. Fuhr, Jr, PhD, Steve Pociask, MA

Stakeholder Perspective

The Hidden Market of Counterfeit Drugs a Concern for All Stakeholders

by James T. Kenney, RPh, MBA

Business

The Economic Burden of Ischemic Stroke and Major Hemorrhage in Medicare Beneficiaries with Nonvalvular Atrial Fibrillation: A Retrospective Claims Analysis

Kathryn Fitch, RN, MEd, Jonah Broulette, ASA, MAAA, Winghan Jacqueline Kwong, PharmD, PhD

Stakeholder Perspective

The Clinical Toll of Nonvalvular Atrial Fibrillation Poses Significant Economic Burden

by Raymond L. Singer, MD, MMM, CPE

Business

The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy- Induced Nausea and Vomiting: Systematic Review of the Literature

Michael S. Broder, MD, MSHS, Claudio Faria, PharmD, MPH, Annette Powers, PharmD, MBA, Jehangeer Sunderji, MD, Dasha Cherepanov, PhD

Stakeholder Perspective

The Value of Pharmaceuticals in the Prevention and Treatment of CINV

by Atheer A. Kaddis, PharmD

Business

Current Challenges in Health Economic Modeling of Cancer Therapies: A Research Inquiry

Jeffrey D. Miller, MS, Kathleen A. Foley, PhD, Mason W. Russell, MAPE

Stakeholder Perspective

Disruptive Innovation, Uncertain Value, and Economic Modeling in Oncology

by Michael F. Murphy, MD, PhD

Business

Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend

Christopher M. Blanchette, PhD, MBA, Nicholas J. Gross, MD, PhD, Pablo Altman, MD, MBA, F. Randy Vogenberg, PhD, FASHP

Stakeholder Perspective

Chronic Obstructive Pulmonary Disease Remains a Growing Population Health Concern

Business

Resource Utilization and Cost in a Commercially Insured Population with Schizophrenia

Kathryn Fitch, RN, MEd, Kosuke Iwasaki, FIAJ, MAAA, Kathleen F. Villa, MS

Stakeholder Perspective

Schizophrenia: “The Forgotten Illness”?

by Atheer A. Kaddis, PharmD

Page 7 of 14
Results 61 - 70 of 135